Evidence map›Paper›PMID 42842149›Full record

ArticleEndocrine2026

Activator of Sirt6 exerts antitumor activity in pituitary neuroendocrine tumors.

Hong Yao, Beibei Fan, Chuanbao Li, Desheng Chen, Zhuoyi Tang, Jingwei Ye, Weiting Gu, Yijun Cheng, Hao Tang, Shaojian Lin and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hong Yao *Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Beibei Fan *Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Chuanbao Li *Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Desheng ChenDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Zhuoyi TangDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jingwei YeDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Weiting GuDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yijun ChengDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Hao TangDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Shaojian LinDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Li XueDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. royxueli@126.com.
Yanting LiuDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. yantingliu1993@aliyun.com.
Zhe Bao WuDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhebaowu@aliyun.com.

Funding

National Natural Science Foundation of China 82000749
6 · The paper itself

Abstract

contextPituitary neuroendocrine tumor (PitNET) is one of the most common intracranial neuroendocrine tumors. Surgical resection is the first choice for most subtypes of PitNETs. However, radical removal of invasive tumors remains challenging. A novel pharmacological therapy is objectively needed. Sirtuin 6 (Sirt6) is a member of the NAD

objectiveIn the study, we investigated the expression of Sirt6 and the antitumor effect of the Sirt6 activator MDL-800 in PitNETs.

methodsThe expression of Sirt6 was detected in PitNET and cell lines by RNA-seq, immunohistochemistry, and western blotting. To test Sirt6 and its activator MDL-800, the cell viability, clone formation, and xenograft experiment were conducted. Autophagy was evaluated by microscopy and western blotting analysis. The efficacy of MDL-800 in the human primary PitNET cells was also investigated by the cell viability assay.

resultsLow expression of Sirt6 was found in PitNET tissues and two pituitary cell lines. Sirt6 inhibited cell proliferation and clone formation. Treatment with MDL-800 suppressed cell growth in vitro and in vivo. Further mechanistic studies showed that MDL-800 could lead to lethal autophagy and exert an antitumor effect in human primary PitNET cells.

conclusionOur results suggest that activation of Sirt6 by its selective activator MDL-800 is a promising therapy for PitNETs.

Indexed as

Antineoplastic AgentsNeuroendocrine TumorsPituitary NeoplasmsSirtuinsAnimalsAutophagyCell Line, TumorCell ProliferationCell SurvivalFemaleHumansMaleMiceMice, NudeXenograft Model Antitumor AssaysAntineoplastic AgentsSIRT6 protein, humanSirtuins

Identifiers

PMID42842149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.